Raythera Inc. has identified TNF-α modulators reported to be useful for the treatment of inflammatory disorders, autoimmune disease, neurological disorders, pain, cardiovascular disorders, cancer, metabolic disorders and eye disorders.
Virginia Commonwealth University has synthesized nitrogen-walk derivatives of NAN acting as µ-opioid receptor modulators reported to be useful for the treatment of pain, opioid dependency and neurological disorders.
The U.S. Patent and Trademark Office has reversed a 2022 agency memorandum on discretionary denials of patent procedures, such as inter partes reviews.
Taichengsi (Shanghai) Biomedical Co. Ltd. has described antibody-drug conjugates comprising an antibody covalently bound to a cytotoxic drug through a bivalent olefin linker optionally consisting of an isotope-labeled compound reported to be useful for the treatment of cancer.
Shenzhen Hightide Biotechnology Ltd. has divulged prodrugs and derivatives of 2,4-dinitro phenol reported to be useful for the treatment of obesity, diabetes, liver disease, heart disease, renal failure, neurodegenerative diseases and aging, among others.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. has disclosed cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
A recent patent filing from Verily Life Sciences LLC seeks protection for the development of an ophthalmic drug delivery device with sensors and a camera which allow the delivery of a specific or controlled dose of a therapeutic agent in vapor form to a patient’s eye.
RSS
